121 related articles for article (PubMed ID: 2173004)
21. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis--a comparison with low molecular weight heparin.
Holst J; Lindblad B; Bergqvist D; Nordfang O; Ostergaard PB; Petersen JG; Nielsen G; Hedner U
Thromb Haemost; 1994 Feb; 71(2):214-9. PubMed ID: 8191401
[TBL] [Abstract][Full Text] [Related]
22. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism.
Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M
Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427
[TBL] [Abstract][Full Text] [Related]
24. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein].
Juhan-Vague I; Stassen JM; Alessi MC; de Cock F; Serradimigni A; Collen D
J Mal Vasc; 1987; 12 Suppl B():64-5. PubMed ID: 2834493
[TBL] [Abstract][Full Text] [Related]
25. The influence of low molecular weight heparin in combination with dihydroergotamine on experimental thrombosis and haemostasis.
Bergqvist D; Nilsson B
Thromb Haemost; 1987 Oct; 58(3):893-5. PubMed ID: 2829377
[TBL] [Abstract][Full Text] [Related]
26. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities.
Fonseca RJ; Oliveira SN; Melo FR; Pereira MG; Benevides NM; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):539-45. PubMed ID: 18327402
[TBL] [Abstract][Full Text] [Related]
27. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
28. Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis.
Kaiser B; Simon A; Markwardt F
Thromb Haemost; 1990 Feb; 63(1):44-7. PubMed ID: 2140204
[TBL] [Abstract][Full Text] [Related]
29. [Fibrinolytic complexes of low-molecular heparin and acetylsalicylic acid].
Kudriashov BA; Pastorova VE; Liapina LA; Kondashevskaia MV
Biull Eksp Biol Med; 1992 Jul; 114(8):141-3. PubMed ID: 1334726
[TBL] [Abstract][Full Text] [Related]
30. Heparin and low molecular weight heparin in thrombosis and beyond.
Mousa SA
Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
[TBL] [Abstract][Full Text] [Related]
31. Low molecular weight heparins: are they different?
Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM
Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031
[TBL] [Abstract][Full Text] [Related]
32. In vivo effects of a low molecular weight heparin fragment on platelet aggregation and platelet dependent hemostasis in dogs.
Ljungberg B; Johnsson H
Thromb Haemost; 1988 Oct; 60(2):232-5. PubMed ID: 2851192
[TBL] [Abstract][Full Text] [Related]
33. Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370.
Colucci M; Rossiello MR; Barbanti M; Calanni F; Semeraro N
Thromb Haemost; 1998 Aug; 80(2):338-41. PubMed ID: 9716163
[TBL] [Abstract][Full Text] [Related]
34. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
35. Antithrombotic effect of OP/LMWH by subcutaneous route in rats.
Fantuz M; Milani R; Andriuoli G; Mastacchi R; Barbanti M
Arch Int Pharmacodyn Ther; 1986 Aug; 282(2):328-34. PubMed ID: 3767531
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of the antithrombotic effects of pentoxifylline, acetylsalicylic acid and low molecular weight heparin in the laser model of thrombosis].
Krupiński K; Breddin HK; Bielawiec M; Płonowski A
Kardiol Pol; 1992 Mar; 36(3):142-5. PubMed ID: 1318982
[TBL] [Abstract][Full Text] [Related]
37. [Fibrinolytic and anticoagulant complexes of low-molecular heparin with tuftsin].
Kudriashov BA; Ashmarin IP; Liapina LA; Pastorova VE
Biull Eksp Biol Med; 1992 Dec; 114(12):609-11. PubMed ID: 1337992
[TBL] [Abstract][Full Text] [Related]
38. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
[TBL] [Abstract][Full Text] [Related]
39. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP
Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120
[TBL] [Abstract][Full Text] [Related]
40. Antithrombotic activity of a novel C-terminal hirudin analog in experimental animals.
Broersma RJ; Kutcher LW; Heminger EF; Krstenansky JL; Marshall FN
Thromb Haemost; 1991 Apr; 65(4):377-81. PubMed ID: 2057920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
